Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07493161

Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL

This is an open-label, prospective clinical cohort study evaluating the efficacy and safety of reduced-intensity chemotherapy combined with targeted therapy and immunotherapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study consists of two integrated parts. The first part is a randomized controlled comparison to investigate the role of venetoclax, a BCL2 inhibitor, when added to a backbone of olverembatinib (a third-generation TKI) and reduced-intensity chemotherapy (VPVO regimen) during the first three cycles of induction/consolidation therapy. The second part is a single-arm exploration of inotuzumab ozogamicin (InO) combined with TKI and chemotherapy as a consolidation strategy for patients who complete the 90-day primary endpoint assessment but do not receive blinatumomab, offering an alternative to blinatumomab-based regimens. The primary endpoint for the venetoclax part is the rate of BCR-ABL < 0.01% at day 90. The primary endpoint for the InO consolidation part is modified event-free survival (EFS) from the start of InO treatment. Key secondary endpoints include overall survival (OS), relapse-free survival (RFS), cumulative incidence of molecular and hematologic relapse, NGS MRD negativity rates, and safety profiles including cardiovascular events and SOS/VOD. The study aims to enroll 110 patients in the initial phase and an additional 78 patients for the InO consolidation phase.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Ph+ ALL

Age range

14 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Blood Diseases Hospital

Tianjin, Tianjin Municipality, 300020, China

Location status: Recruiting

Location contact

Hui Wei, MD

CONTACT

[email protected]

86-13132507161

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Newly diagnosed ALL with t(9;22)(q34;q11) or BCR::ABL1 positivity (by PCR or FISH).
  • Age ≥ 14 years.
  • ECOG performance status ≤ 2.
  • Adequate organ function: Total bilirubin <1.5x ULN; AST/ALT ≤2.5x ULN; Serum creatinine <2x ULN; Cardiac enzymes <2x ULN; Serum amylase ≤1.5x ULN; Left ventricular ejection fraction (LVEF) >45%.
  • Male and female patients of childbearing potential must agree to use effective contraception.
  • Signed informed consent.

Exclusion criteria

  • Diagnosis of chronic myeloid leukemia in chronic, accelerated, or blast phase.
  • Prior systemic anti-leukemic therapy for ALL (except corticosteroids or hydroxyurea for cytoreduction prior to enrollment).
  • Myocardial infarction within 12 months prior to enrollment; uncontrolled/unstable angina, congestive heart failure, uncontrolled hypertension or arrhythmia.
  • Uncontrolled active severe infection.
  • Active psychiatric illness that may hinder treatment completion or informed consent.
  • Any other condition deemed unsuitable for the study by the investigator.

Treatment and study plan

Olverembatinib

Drug

Third-generation tyrosine kinase inhibitor (TKI) targeting BCR-ABL1, including T315I mutation.nduction & Consolidation: 40mg every other day.

After achieving CMR: Reduced to 20mg every other day during maintenance.

Venetoclax

Drug

BCL-2 inhibitor. Used only in the experimental arm.Induction: Ramp-up: 100mg D1, 200mg D2, 400mg D3-28.

Consolidation: 400mg D1-7.

Blinatumomab

Drug

CD19/CD3 bispecific T-cell engager (BiTE). Optional add-on therapy 1.Start from 4 cycle.

Duration: 1-4 cycles (each cycle = 28 days), intercalated with chemotherapy cycles.

Note: If ≥3 cycles given,cycle 8 and 9 are omitted.

Chemotherapy Backbone Regimens

Drug

Induction (VPO/VPVO): Vincristine + Prednisone + Olverembatinib (± Venetoclax).

Consolidation (VOVP/OVP): Vincristine +Olverembatinib + Prednisone (± Venetoclax).

HD-MTX: High-dose methotrexate with leucovorin rescue in cycle 4,6,8.

ID-AraC: Intermediate-dose cytarabine in cycle 5,7,9.

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Other

Recommended for patients with MRD ≥0.01% after two treatment blocks.

Inotuzumab ozogamicin

Drug

Optional add-on therapy 2. Start from 4 cycle. at a total dose of 2 mg per cycle. TKI should be discontinued 5 days prior to InO administration, and olverembatinib oral therapy should be resumed one week after InO administration. For patients who remain NGS MRD-positive after one cycle of InO, a repeat cycle of InO may be considered.

Note: If 2 cycles given,cycle 9 are omitted.

Primary outcomes

  1. Rate of BCR::ABL1 ≤0.01% at 90 days (after three cycles of treatment)

    Time frame: up to 90 days

  2. Modified Event-Free Survival (mEFS) from start of InO consolidation

    Time frame: From the start of InO consolidation therapy up to 2 years

Secondary outcomes

  1. Overall Survival

    Time frame: up to 5 years

  2. Relapse-Free Survival

    Time frame: up to 5 years

  3. Cumulative incidence of molecular relapse

    Time frame: up to 5 years

  4. Cumulative incidence of hematologic relapse

    Time frame: up to 5 years

  5. Proportion of patients with next-generation sequencing minimal residual disease <0.01% after three cycles of treatment (90 days)

    Time frame: up to 90 days

  6. Proportion of patients with next-generation sequencing minimal residual disease <0.01% at the end of consolidation therapy

    Time frame: up to 1 year

  7. Incidence of treatment-related cardiovascular events

    Time frame: up to 5 years from the initiation of treatment

  8. Proportion of patients with BCR::ABL1 ≤0.01% at completion of consolidation therapy

    Time frame: up to 9 months

  9. Incidence of SOS/VOD

    Time frame: From the start of InO consolidation therapy up to 6 months post-treatment

  10. Hematopoietic Stem Cell Transplantation (HSCT) rate

    Time frame: up to 5 years

Study contacts

Contact information is provided by the study sponsor or research team.

Hui Wei, MD

CONTACT

[email protected]

13132507161

Sponsors and collaborators

Lead sponsor

Institute of Hematology & Blood Diseases Hospital, China

Other

Registry information

Official study title

Low-intensity Chemotherapy Combined With Targeted-Immunotherapy for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Prospective Clinical Cohort Study

Important dates

Study start
2026
Primary completion
2028
Study completion
2030
First posted
Mar 25, 2026
Registry last updated
Jul 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.